scholarly journals Nasopharyngeal diffuse large B-cells lymphoma causing acute airway obstruction amid COVID-19 crisis: an anaesthetist’s nightmare

2021 ◽  
Vol 14 (1) ◽  
pp. e241008
Author(s):  
Tat Boon Yeap ◽  
Ming Kai Teah ◽  
Yen Ju Joanne Quay ◽  
Melvin Teck Fui Wong

Acute stridor is often an airway emergency. We present a valuable experience handling an elderly woman who was initially treated as COVID-19 positive during the pandemic in November 2020. She needed an urgent tracheostomy due to nasopharyngeal (NP) diffuse large B-cell lymphoma causing acute airway obstruction. Fortunately, 1 hour later, her NP swab real-time PCR test result returned as SARS-CoV-2 negative. This interesting article depicts the importance of adequate preparations when handling potentially infectious patients with anticipated difficult airway and the perioperative issues associated with it.

2016 ◽  
Vol 10 (2) ◽  
pp. 112-116 ◽  
Author(s):  
Ming-Wei Cheng ◽  
Alice Ying-Jung Wu ◽  
Chang-Pang Liu ◽  
Ken-Hong Lim ◽  
Shu-Ling Weng ◽  
...  

2017 ◽  
Vol 2017 ◽  
pp. 1-4 ◽  
Author(s):  
Bushra Rahman ◽  
Jawad Bilal ◽  
Qurat Ul Ain Riaz Sipra ◽  
Irbaz Bin Riaz

Localized laryngeal lymphoma is a rare entity with an incidence of less than 1% of all laryngeal neoplasms. Diffuse large B-cell lymphoma (DLBCL) is the most common type of laryngeal neoplasms. Here, we describe a case of a young 28-year-old female with large B-cell lymphoma who remained undiagnosed for a long time owing to a myriad of nonspecific presentation including “wheezing.” Although primary laryngeal lymphomas constitute a diagnostic challenge since they are rare, one should have a high index of suspicion for lymphoma of the larynx in patients presenting with unresolved wheezing as it can present catastrophically with acute airway obstruction requiring immediate surgical intervention which was observed in this case. Treatment includes radiotherapy, chemotherapy, immunotherapy, or a combination of these. We hope that the discussions ensuing from case reports regarding uncommon presentations of laryngeal lymphoma may spur the formation of regional/international databases for the description of lymphomas with unusual presentations. This effort can lead to in-depth study of cases and prompt awareness of “rare and subtle presentations” of laryngeal lymphoma.


Author(s):  
Wannitta E. Ting Wong ◽  
Ahmad Nordin Bin Afandi

<p class="abstract">Primary thyroid lymphoma and laryngeal lymphoma are rare malignancies of the head and neck region. Airway obstruction caused by primary thyroid lymphoma is mainly by means of direct compression of trachea by huge thyroid mass. We present the first case report of diffuse large B cell lymphoma of thyroid gland with extension to pyriform fossa, in the absence of preexisting chronic thyroiditis. In this case, emergency airway obstruction was caused by direct extension of disease into pyriform fossa, occluding laryngeal inlet. We reviewed English literature between 1981 and 2018 for cases of primary thyroid lymphoma. There are no reported cases of primary thyroid lymphoma with direct extension into pyriform fossa. This presentation posed a great challenge in securing a patent airway by means of oral intubation and tracheostomy.</p><p class="abstract"> </p>


Praxis ◽  
2016 ◽  
Vol 105 (1) ◽  
pp. 47-52 ◽  
Author(s):  
Andreas Lohri

Zusammenfassung. Maligne Lymphome unterteilen sich zwar in über 60 Entitäten, das grosszellige B-Zell-Lymphom, das follikuläre Lymphom, der Hodgkin und das Mantelzell-Lymphom machen aber mehr als die Hälfte aller Lymphome aus. Im revidierten Ann Arbor staging system gelten die Suffixe «A» und «B» nur noch für den Hodgkin. «E» erscheint nur noch bei Stadien I und II. Eine Knochenmarksuntersuchung wird beim Hodgkin nicht mehr verlangt, beim DLBCL (Diffuse large B cell lymphoma) nur, falls das PET keinen Knochenmark-Befall zeigt. Der PET-Untersuchung, speziell dem Interim-PET, kommt eine entscheidende Bedeutung zu. PET-gesteuerte Therapien führen zu weniger Toxizität. Gezielt wirkende Medikamente mit eindrücklicher Wirksamkeit wurden neu zugelassen. Deren Kosten sind hoch. Eine strahlen- und chemotherapiefreie Behandlung maligner Lymphome wird in Zukunft möglich sein.


Sign in / Sign up

Export Citation Format

Share Document